[Adalimumab].
Rheumatoid arthritis (RA) is a systemic autoimmune disease characterized by inflammation of the synovial joints, and eventual destruction of cartilage and bone, as well as various extra-articular signs and symptoms. The TNF-alpha blocker adalimumab (ADA) is a fully human IgG1 monoclonal antibody that neutralizes both soluble and membrane-bound TNF in humans. Several clinical trials have provided compelling evidence of the safety and clinical efficacy of ADA for both the induction and maintenance of remission in RA. Moreover, the beneficial effects of ADA on bone destruction seen in the joint of RA have been demonstrated by recent clinical investigation. This review will discuss the clinical efficacy and utility of ADA in the management of RA.